Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis

Clinical Microbiology and Infection

Volumn 11, Issue 12, 2005, Pages 999-1004

  Gavalda Santapau J ^a   Martin T ^a   Lopez P ^a   Gomis, X ^a   Ramirez J L ^a   Rodriguez D ^a   Len, O ^a   Puigfel, Y ^a   Ruiz, I ^a   Pahissa, A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Amphotericin B; Animal model; Aspergillosis; Invasive disease; Loading doses; Therapy

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; GLUCOSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS FUMIGATUS; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; LUNG ASPERGILLOSIS; LUNG WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALIA; ASPERGILLUS FUMIGATUS;

EID: 28644447491     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01262.x     Document Type: Article

References (23)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
2. Link H, Böhme A, Comely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO); Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82(suppl 2): 133-140.
3. Denning DW, Kibler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-240.
4. Gavaldà J, Ruiz I. Recomendaciones para el tratamiento de la infección por Aspergillus spp. Enf Infecc Microbiol Clín 2003; 21: 571-578.
5. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28(suppl B): 83-91.
6. Francis P, Lee JW, Hoffman A et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994; 169: 356-368.
7. Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J Antimicrob Chemother 1996; 38: 215-225.
8. Martín MT, Gavaldà J, López P et al. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother 2003; 52: 1032-1034.
9. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496.
10. de Marie S, Janknegt R, Bakker-Woudenberg AJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33: 907-916.
11. Walsh TJ, Yeldandi V, McEvoy M et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998; 42: 2391-2398.
12. Adler-Moore JP, Olson JA, Proffitt RT. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 2004; 54: 1096-1102.
13. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: proposed standard. Document M-38P. Wayne, PA: NCCLS, 1998.
14. Niki Y, Bernard EM, Edwards FF, Schmitt HJ, Yu B, Armstrong D. Model of recurrent pulmonary aspergillosis in rats. J Clin Microbiol 1991; 29: 1317-1322.
15. Fluckiger U, Francioli P, Blaser J, Glauser MP, Moreillon P. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J Infect Dis 1994; 169: 1397-1400.
16. Lehmann PF, White LO. Chitin assay used to demonstrate renal localization and cortisone-enhanced growth of Aspergillus fumigatus mycelium in mice. Infect Immun 1975; 12: 987-992.
17. Plassard C. Assay of fungal chitin and estimation of mycelial biomass. In: Muzzarelli RAA, Peter MG, eds. Chitin handbook. Grottammare: Atec Edizioni, 1997; 27-31.
18. Kisch AL, Maydew RP, Evan AP. Synergistic nephrotoxicity of amphotericin B and cortisone acetate in mice. J Infect Dis 1978; 137: 789-794.
19. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-618.
20. Heinemann V, Bosse D, Jehn U et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother 1997; 41: 1275-1280.
21. Becker MJ, de Marie S, Fens MH, Hop WC, Verbrugh HA, Bakker-Woudenberg IA. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. J Antimicrob Chemother 2002; 49: 813-820.
22. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
23. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP. Spectrum of Aspergillus infection in lung transplant recipients. Chest 2001; 119: 169-175.